Trial reportBrain and behavior2026
3MDR Therapy Reduces Symptoms of PTSD and Related Conditions in Canadian Military Members and Veterans, Public Safety Personnel, and Clinical Personnel.
Trial report in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveMilitary Veterans, public safety personnel (police, fire fighters, paramedics, and others), and frontline healthcare workers are at elevated risk of posttraumatic stress disorder (PTSD) due to trauma exposure. Multimodal motion-assisted memory desensitization and reconsolidation (3MDR) therapy is an innovative therapy for PTSD and trauma-related mental health concerns, originally developed for military members and Veterans. The purpose of this study was to extend evidence for the effectiveness of 3MDR in Canadian military Veterans and to test it with public safety personnel and frontline healthcare workers.
methodsThis study is a longitudinal mixed-methods clinical trial. We examined 48 participants with PTSD from Alberta, Canada. Twenty-two participants had treatment-resistant PTSD. Participants were active military members or Veterans (n = 17), public safety personnel (n = 21), and/or healthcare workers (n = 21). Participants received a 10- to 14-week course of 3MDR therapy. Quantitative data were collected pretreatment, at the end of treatment, and longitudinally at 3, 6, and 12 months after completion of 3MDR.
resultsData from 48 participants were analyzed. Data collected pre- and post-3MDR therapy showed both statistically and clinically significant reductions in symptom scores for PTSD (CAPS-5 clinical interview: 46.4 ± 2.2 to 25.1 ± 3.4, mean ± standard error; PCL-5 questionnaire: 48.5 ± 2.2 to 32.2 ± 3.0), depression (PHQ-9: 14.3 ± 1.0 to 9.8 ± 1.0), anxiety (GAD-7: 12.2 ± 0.9 to 8.3 ± 0.9), and difficulties with life functioning (OQ-45: 92.0 ± 3.9 to 77.3 ± 4.4). These improvements were maintained through to 12 months follow-up. Resilience (CD-RISC-25), which was assessed pre- and post-3MDR but not at follow-up, also showed significant improvements over the course of 3MDR therapy. All results survived multiple comparison correction.
conclusionThese results support the growing body of literature illustrating 3MDR as an effective treatment for military-related PTSD as well as PTSD-related mental health conditions in public safety personnel and healthcare workers. These results also extend the period of post-3MDR follow-up to 12 months in a sample of Canadian 3MDR participants, from 6 months follow-up in earlier Canadian 3MDR studies.
trial registrationISRCTN Registry 11264368; http://www.isrctn.com/ISRCTN11264368. International Registered Report Identifier (IRRID): DERR1-10.2196/20620.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.